{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:18:39Z","timestamp":1791519519836,"version":"4.3.4"},"reference-count":131,"publisher":"Portland Press Ltd.","issue":"20","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,22]]},"abstract":"<jats:p>Neutrophils are innate immune effector cells that play a vital role in host defense against infection. They exert antimicrobial activities through degranulation, phagocytosis, intracellular killing, production of reactive oxygen species, and neutrophil extracellular traps. Dysregulation of neutrophil abundance, phenotype, and immune activity is a commonly observed inflammatory feature of chronic obstructive pulmonary disease (COPD), a chronic inflammatory disorder of the lungs with no effective cure. Here, we review the clinical association and involvement of neutrophils in COPD pathogenesis, progression, and exacerbation. The association between neutrophilia, airway microbial imbalance (dysbiosis), and clinical manifestations of COPD is described. We summarize the impact (or lack of) of current treatments, including inhaled corticosteroids, macrolide antibiotics, and phosphodiesterase inhibitors, on neutrophilic inflammation or neutrophilia-associated features. Finally, we review potential future therapeutic options to address neutrophilic inflammation in COPD currently in clinical development, including anti-alarmins and inhibitors of neutrophil mediators.<\/jats:p>","DOI":"10.1042\/cs20255452","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:32:54Z","timestamp":1761147174000},"page":"1199-1214","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["COPD: the role of neutrophils in inflammation, pathophysiology, and as drug targets"],"prefix":"10.1042","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8587-1774","authenticated-orcid":false,"given":"Michael","family":"Fricker","sequence":"first","affiliation":[{"name":"1School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia"},{"name":"2Asthma and Breathing Research Program, Hunter Medical Research Institute, Newcastle, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6038-7150","authenticated-orcid":false,"given":"Ravi","family":"Lokwani","sequence":"additional","affiliation":[{"name":"3School of Pharmacy, Chapman University, Irvine, California, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"2025102211324753000_CS-2025-5452C1","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1038\/s41590-024-02006-5","article-title":"The diverse roles of neutrophils from protection to pathogenesis","volume":"25","author":"Herro","year":"2024","journal-title":"Nat. Immunol."},{"key":"2025102211324753000_CS-2025-5452C2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jaci.2022.12.004","article-title":"Neutrophils in host defense, healing, and hypersensitivity: Dynamic cells within a dynamic host","volume":"151","author":"Siwicki","year":"2023","journal-title":"J. Allergy Clin. Immunol"},{"key":"2025102211324753000_CS-2025-5452C3","article-title":"Neutrophil diversity and function in health and disease","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"2025102211324753000_CS-2025-5452C4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41423-023-01058-1","article-title":"Neutrophil diversity and plasticity: implications for organ transplantation","volume":"20","author":"Qu","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"2025102211324753000_CS-2025-5452C5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.602963","article-title":"Neutrophils: need for standardized nomenclature","volume":"12","author":"McKenna","year":"2021","journal-title":"Front. Immunol."},{"key":"2025102211324753000_CS-2025-5452C6","article-title":"CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease","volume":"48 Suppl 2","author":"De Filippo","year":"2018","journal-title":"Eur. J. Clin. Invest."},{"key":"2025102211324753000_CS-2025-5452C7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nri3399","article-title":"Neutrophil recruitment and function in health and inflammation","volume":"13","author":"Kolaczkowska","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"2025102211324753000_CS-2025-5452C8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.immuni.2023.11.007","article-title":"trans-Endothelial neutrophil migration activates bactericidal function via Piezo1 mechanosensing","volume":"57","author":"Mukhopadhyay","year":"2024","journal-title":"Immunity"},{"key":"2025102211324753000_CS-2025-5452C9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1146\/annurev-immunol-020711-074942","article-title":"Neutrophil function: from mechanisms to disease","volume":"30","author":"Amulic","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"2025102211324753000_CS-2025-5452C10","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aao1716","article-title":"The pseudokinase MLKL activates PAD4-dependent NET formation in necroptotic neutrophils","volume":"11","author":"D\u2019Cruz","year":"2018","journal-title":"Sci. Signal."},{"key":"2025102211324753000_CS-2025-5452C11","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1111\/febs.15589","article-title":"NET formation - mechanisms and how they relate to other cell death pathways","volume":"288","author":"Rosazza","year":"2021","journal-title":"FEBS J."},{"key":"2025102211324753000_CS-2025-5452C12","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj1397","article-title":"NET formation is a default epigenetic program controlled by PAD4 in apoptotic neutrophils","volume":"9","author":"Zhu","year":"2023","journal-title":"Sci. Adv."},{"key":"2025102211324753000_CS-2025-5452C13","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aao4747","article-title":"Neutrophil cytoplasts induce TH17 differentiation and skew inflammation toward neutrophilia in severe asthma","volume":"3","author":"Krishnamoorthy","year":"2018","journal-title":"Sci. Immunol."},{"key":"2025102211324753000_CS-2025-5452C14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12016-020-08804-7","article-title":"A review of neutrophil extracellular traps (NETs) in Disease: Potential Anti-NETs Therapeutics","volume":"61","author":"Mutua","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"2025102211324753000_CS-2025-5452C15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00239-2023","article-title":"Global initiative for chronic obstructive lung disease 2023 Report: GOLD executive summary","volume":"61","author":"Agust\u00ed","year":"2023","journal-title":"Eur. Respir. J."},{"key":"2025102211324753000_CS-2025-5452C16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1183\/09031936.06.00052705","article-title":"Wood smoke exposure and risk of chronic obstructive pulmonary disease","volume":"27","author":"Orozco-Levi","year":"2006","journal-title":"Eur. Respir. J."},{"key":"2025102211324753000_CS-2025-5452C17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1289\/ehp.1408200","article-title":"Exposure to household air pollution from wood combustion and association with respiratory symptoms and lung function in nonsmoking women: results from the RESPIRE trial, Guatemala","volume":"123","author":"Pope","year":"2015","journal-title":"Environ. Health Perspect."},{"key":"2025102211324753000_CS-2025-5452C18","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00698-2017","article-title":"ERS\/ATS workshop report on respiratory health effects of household air pollution","volume":"51","author":"Sood","year":"2018","journal-title":"Eur. Respir. J."},{"key":"2025102211324753000_CS-2025-5452C19","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/S0140-6736(05)66781-5","article-title":"Alpha1-antitrypsin deficiency","volume":"365","author":"Stoller","year":"2005","journal-title":"Lancet"},{"key":"2025102211324753000_CS-2025-5452C20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaci.2014.06.035","article-title":"Biological clustering supports both \u201cDutch\u201d and \u201cBritish\u201d hypotheses of asthma and chronic obstructive pulmonary disease","volume":"135","author":"Ghebre","year":"2015","journal-title":"J. Allergy Clin. Immunol"},{"key":"2025102211324753000_CS-2025-5452C21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1440-1843.2006.00784.x","article-title":"Inflammatory subtypes in asthma: assessment and identification using induced sputum","volume":"11","author":"Simpson","year":"2006","journal-title":"Respirology"},{"key":"2025102211324753000_CS-2025-5452C22","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0140-6736(00)02872-5","article-title":"Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial","volume":"356","author":"Brightling","year":"2000","journal-title":"Lancet"},{"key":"2025102211324753000_CS-2025-5452C23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12931-017-0570-5","article-title":"Blood and sputum eosinophils in COPD; relationship with bacterial load","volume":"18","author":"Kolsum","year":"2017","journal-title":"Respir. Res."},{"key":"2025102211324753000_CS-2025-5452C24","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1164\/rccm.201912-2384PP","article-title":"Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease","volume":"202","author":"Singh","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C25","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of Type 2 Inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"2025102211324753000_CS-2025-5452C26","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/all.14741","article-title":"Molecular markers of type 2 airway inflammation are similar between eosinophilic severe asthma and eosinophilic chronic obstructive pulmonary disease","volume":"76","author":"Fricker","year":"2021","journal-title":"Allergy"},{"key":"2025102211324753000_CS-2025-5452C27","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2147\/COPD.S305380","article-title":"Sputum gene expression reveals dysregulation of mast cells and basophils in eosinophilic COPD","volume":"16","author":"Winter","year":"2021","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"2025102211324753000_CS-2025-5452C28","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.202009-3448OC","article-title":"Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations: a multicohort longitudinal analysis","volume":"203","author":"Wang","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.cyto.2011.07.010","article-title":"Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease","volume":"56","author":"Moermans","year":"2011","journal-title":"Cytokine"},{"key":"2025102211324753000_CS-2025-5452C30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/15412555.2020.1833853","article-title":"Comprehensive Cluster Analysis for COPD Including Systemic and Airway Inflammatory Markers","volume":"17","author":"Zahraei","year":"2020","journal-title":"COPD"},{"key":"2025102211324753000_CS-2025-5452C31","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C32","article-title":"Inter-relationships among neutrophilic inflammation, air trapping and future exacerbation in COPD: an analysis of ECOPD study","volume":"10","author":"Yang","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"2025102211324753000_CS-2025-5452C33","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2147\/COPD.S100338","article-title":"Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD","volume":"11","author":"Negewo","year":"2016","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"2025102211324753000_CS-2025-5452C34","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.rmed.2009.01.021","article-title":"Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease","volume":"103","author":"Higashimoto","year":"2009","journal-title":"Respir. Med."},{"key":"2025102211324753000_CS-2025-5452C35","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-014-0114-1","article-title":"Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease","volume":"15","author":"Singh","year":"2014","journal-title":"Respir. Res."},{"key":"2025102211324753000_CS-2025-5452C36","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.chom.2023.04.018","article-title":"Airway dysbiosis accelerates lung function decline in chronic obstructive pulmonary disease","volume":"31","author":"Liang","year":"2023","journal-title":"Cell Host Microbe"},{"key":"2025102211324753000_CS-2025-5452C37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jaci.2020.02.040","article-title":"The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease","volume":"147","author":"Dicker","year":"2021","journal-title":"J. Allergy Clin. Immunol"},{"key":"2025102211324753000_CS-2025-5452C38","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/15412555.2018.1476475","article-title":"Neutrophilic inflammation in the pathogenesis of chronic obstructive pulmonary disease","volume":"15","author":"Butler","year":"2018","journal-title":"COPD"},{"key":"2025102211324753000_CS-2025-5452C39","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112525","article-title":"Systemic alterations in neutrophils and their precursors in early-stage chronic obstructive pulmonary disease","volume":"42","author":"Kapellos","year":"2023","journal-title":"Cell Rep."},{"key":"2025102211324753000_CS-2025-5452C40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jaci.2016.05.011","article-title":"Inflammatory mechanisms in patients with chronic obstructive pulmonary disease","volume":"138","author":"Barnes","year":"2016","journal-title":"J. Allergy Clin. Immunol"},{"key":"2025102211324753000_CS-2025-5452C41","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/bmj.332.7551.1202","article-title":"Pathology, pathogenesis, and pathophysiology","volume":"332","author":"MacNee","year":"2006","journal-title":"BMJ"},{"key":"2025102211324753000_CS-2025-5452C42","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccm.2012.08.003","article-title":"Indoor fuel exposure and the lung in both developing and developed countries: an update","volume":"33","author":"Sood","year":"2012","journal-title":"Clin. Chest Med"},{"key":"2025102211324753000_CS-2025-5452C43","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-022-02153-z","article-title":"The effects of epithelial-mesenchymal transitions in COPD induced by cigarette smoke: an update","volume":"23","author":"Su","year":"2022","journal-title":"Respir. Res."},{"key":"2025102211324753000_CS-2025-5452C44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145961","article-title":"Characterization and quantification of innate lymphoid cell subsets in human lung","volume":"11","author":"De Grove","year":"2016","journal-title":"PLoS ONE"},{"key":"2025102211324753000_CS-2025-5452C45","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/all.13760","article-title":"Inflammatory endotypes in COPD","volume":"74","author":"Barnes","year":"2019","journal-title":"Allergy"},{"key":"2025102211324753000_CS-2025-5452C46","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024330","article-title":"Hypersegmented airway neutrophils and its association with reduced lung function in adults with obstructive airway disease: an exploratory study","volume":"9","author":"Lokwani","year":"2019","journal-title":"BMJ Open"},{"key":"2025102211324753000_CS-2025-5452C47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cell.2018.12.002","article-title":"Activated PMN exosomes: pathogenic entities causing matrix destruction and disease in the lung","volume":"176","author":"Genschmer","year":"2019","journal-title":"Cell"},{"key":"2025102211324753000_CS-2025-5452C48","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13223-020-00440-2","article-title":"Epidermal growth factor upregulates expression of MUC5AC via TMEM16A, in chronic rhinosinusitis with nasal polyps","volume":"16","author":"Jiao","year":"2020","journal-title":"Allergy. Asthma Clin. Immunol."},{"key":"2025102211324753000_CS-2025-5452C49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pharmthera.2009.06.004","article-title":"Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis","volume":"124","author":"Simpson","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"2025102211324753000_CS-2025-5452C50","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/nm.2971","article-title":"Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression","volume":"18","author":"Galb\u00e1n","year":"2012","journal-title":"Nat. Med."},{"key":"2025102211324753000_CS-2025-5452C51","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1513\/pats.200504-045SR","article-title":"Pathogenesis of chronic obstructive pulmonary disease","volume":"2","author":"MacNee","year":"2005","journal-title":"Proc. Am. Thorac. Soc."},{"key":"2025102211324753000_CS-2025-5452C52","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2174\/156801005774912824","article-title":"Inflammatory cells and chronic obstructive pulmonary disease","volume":"4","author":"Tetley","year":"2005","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"key":"2025102211324753000_CS-2025-5452C53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/413735","article-title":"Inflammation and Immune Response in COPD: Where Do We Stand?","volume":"2013","author":"Rovina","year":"2013","journal-title":"Mediators Inflamm."},{"key":"2025102211324753000_CS-2025-5452C54","first-page":"S167","article-title":"Airway inflammation in chronic obstructive pulmonary disease","volume":"6 Suppl 1","author":"Angelis","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"2025102211324753000_CS-2025-5452C55","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0084-2023","article-title":"How inhaled corticosteroids target inflammation in COPD","volume":"32","author":"Lea","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"2025102211324753000_CS-2025-5452C56","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMoa1106955","article-title":"Small-airway obstruction and emphysema in chronic obstructive pulmonary disease","volume":"365","author":"McDonough","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2025102211324753000_CS-2025-5452C57","first-page":"182","article-title":"The definition of emphysema. report of a national heart, lung, and blood institute, division of lung diseases workshop","volume":"132","author":"National Heart, Lung, and Blood Institute, Division of Lung Diseases","year":"1985","journal-title":"Am. Rev. Respir. Dis."},{"key":"2025102211324753000_CS-2025-5452C58","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1378\/chest.10-0705","article-title":"Persistent airway inflammation and emphysema progression on CT scan in ex-smokers observed for 4 years","volume":"139","author":"Miller","year":"2011","journal-title":"Chest"},{"key":"2025102211324753000_CS-2025-5452C59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1513\/pats.200708-126ET","article-title":"Pathogenesis of emphysema: from the bench to the bedside","volume":"5","author":"Sharafkhaneh","year":"2008","journal-title":"Proc. Am. Thorac. Soc."},{"key":"2025102211324753000_CS-2025-5452C60","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/thoraxjnl-2012-202646","article-title":"Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense?","volume":"68","author":"McDonald","year":"2013","journal-title":"Thorax"},{"key":"2025102211324753000_CS-2025-5452C61","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(87)91476-0","article-title":"Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis","volume":"2","author":"Burnett","year":"1987","journal-title":"Lancet"},{"key":"2025102211324753000_CS-2025-5452C62","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1164\/rccm.201008-1285OC","article-title":"Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease","volume":"183","author":"Sapey","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C63","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1378\/chest.11-2348","article-title":"Defective phagocytosis in airways disease","volume":"141","author":"Donnelly","year":"2012","journal-title":"Chest"},{"key":"2025102211324753000_CS-2025-5452C64","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1172\/JCI57990","article-title":"A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1","volume":"122","author":"Pillay","year":"2012","journal-title":"J. Clin. Invest."},{"key":"2025102211324753000_CS-2025-5452C65","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.4049\/jimmunol.1601292","article-title":"Cutting Edge: Helicobacter pylori Induces Nuclear Hypersegmentation and Subtype Differentiation of Human Neutrophils In Vitro","volume":"198","author":"Whitmore","year":"2017","journal-title":"J. Immunol."},{"key":"2025102211324753000_CS-2025-5452C66","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94040","article-title":"Chronic cigarette smoke exposure induces systemic hypoxia that drives intestinal dysfunction","volume":"3","author":"Fricker","year":"2018","journal-title":"JCI Insight"},{"key":"2025102211324753000_CS-2025-5452C67","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1164\/rccm.202006-2467OC","article-title":"Hypoxia increases the potential for neutrophil-mediated endothelial damage in chronic obstructive pulmonary disease","volume":"205","author":"Lodge","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C68","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/resp.12730","article-title":"Neutrophil extracellular traps are associated with inflammation in chronic airway disease","volume":"21","author":"Wright","year":"2016","journal-title":"Respirology"},{"key":"2025102211324753000_CS-2025-5452C69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaci.2017.04.022","article-title":"Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease","volume":"141","author":"Dicker","year":"2018","journal-title":"J. Allergy Clin. Immunol"},{"key":"2025102211324753000_CS-2025-5452C70","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-015-0221-7","article-title":"Neutrophil extracellular trap (NET) formation characterises stable and exacerbated COPD and correlates with airflow limitation","volume":"16","author":"Grabcanovic-Musija","year":"2015","journal-title":"Respir. Res."},{"key":"2025102211324753000_CS-2025-5452C71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097784","article-title":"New aspects on the structure of neutrophil extracellular traps from chronic obstructive pulmonary disease and in vitro generation","volume":"9","author":"Obermayer","year":"2014","journal-title":"PLoS ONE"},{"key":"2025102211324753000_CS-2025-5452C72","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03312-2020","article-title":"Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation and Haemophilus infection in COPD","volume":"58","author":"Winslow","year":"2021","journal-title":"Eur. Respir. J."},{"key":"2025102211324753000_CS-2025-5452C73","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1164\/rccm.201509-1818OC","article-title":"Acute respiratory distress syndrome neutrophils have a distinct phenotype and are resistant to Phosphoinositide 3-Kinase Inhibition","volume":"194","author":"Juss","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C74","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","article-title":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease","volume":"157","author":"Seemungal","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C75","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"key":"2025102211324753000_CS-2025-5452C76","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1378\/chest.121.5.1441","article-title":"Mortality after hospitalization for COPD","volume":"121","author":"Almagro","year":"2002","journal-title":"Chest"},{"key":"2025102211324753000_CS-2025-5452C77","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2213-2600(17)30207-2","article-title":"Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort","volume":"5","author":"Han","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"2025102211324753000_CS-2025-5452C78","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2025102211324753000_CS-2025-5452C79","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1164\/rccm.200506-859OC","article-title":"Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations","volume":"173","author":"Papi","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C80","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-020-01436-7","article-title":"Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD","volume":"21","author":"Lonergan","year":"2020","journal-title":"Respir. Res."},{"key":"2025102211324753000_CS-2025-5452C81","article-title":"Predictive value of neutrophil-to-lymphocyte ratio for adverse outcomes in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: A retrospective study","volume":"103","author":"Vu-Hoai","year":"2024","journal-title":"Medicine (Abingdon)."},{"key":"2025102211324753000_CS-2025-5452C82","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-14-72","article-title":"Neutrophil adhesion molecules in experimental rhinovirus infection in COPD","volume":"14","author":"Mallia","year":"2013","journal-title":"Respir. Res."},{"key":"2025102211324753000_CS-2025-5452C83","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.rmed.2006.01.022","article-title":"Expression of priming-associated cellular markers on neutrophils during an exacerbation of COPD","volume":"100","author":"Oudijk","year":"2006","journal-title":"Respir. Med."},{"key":"2025102211324753000_CS-2025-5452C84","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jaci.2020.03.021","article-title":"Bronchial mucosal inflammation and illness severity in response to experimental rhinovirus infection in COPD","volume":"146","author":"Zhu","year":"2020","journal-title":"J. Allergy Clin. Immunol"},{"key":"2025102211324753000_CS-2025-5452C85","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/resp.12912","article-title":"Increased neutrophil expression of pattern recognition receptors during COPD exacerbations","volume":"22","author":"Pouwels","year":"2017","journal-title":"Respirology"},{"key":"2025102211324753000_CS-2025-5452C86","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.200708-1234OC","article-title":"Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease","volume":"177","author":"Sethi","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C87","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1145-4","article-title":"Neutrophil elastase as a biomarker for bacterial infection in COPD","volume":"20","author":"Thulborn","year":"2019","journal-title":"Respir. Res."},{"key":"2025102211324753000_CS-2025-5452C88","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-50197-0","article-title":"Neutrophil extracellular traps promote immunopathogenesis of virus-induced COPD exacerbations","volume":"15","author":"Katsoulis","year":"2024","journal-title":"Nat. Commun."},{"key":"2025102211324753000_CS-2025-5452C89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(18)30006-7","article-title":"Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials","volume":"6","author":"Bafadhel","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"2025102211324753000_CS-2025-5452C90","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202201-0209PP","article-title":"Blood Eosinophils and chronic obstructive pulmonary disease: a global initiative for chronic obstructive lung disease science committee 2022 Review","volume":"206","author":"Singh","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C91","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/thx.2009.126722","article-title":"Effects of steroid therapy on inflammatory cell subtypes in asthma","volume":"65","author":"Cowan","year":"2010","journal-title":"Thorax"},{"key":"2025102211324753000_CS-2025-5452C92","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/thorax-2021-218555","article-title":"Macrophage migration inhibitory factor promotes glucocorticoid resistance of neutrophilic inflammation in a murine model of severe asthma","volume":"78","author":"Allam","year":"2023","journal-title":"Thorax"},{"key":"2025102211324753000_CS-2025-5452C93","doi-asserted-by":"crossref","first-page":"L1183","DOI":"10.1152\/ajplung.00521.2019","article-title":"The role of MIF in chronic lung diseases: looking beyond inflammation","volume":"318","author":"Florez-Sampedro","year":"2020","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2025102211324753000_CS-2025-5452C94","unstructured":"GOLD\n          . (2025) Global initiative for chronic obstructive lung disease. global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http:\/\/wwwgoldcopdorg"},{"key":"2025102211324753000_CS-2025-5452C95","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/all.16436","article-title":"The bronchodilator and anti-inflammatory effect of long-acting muscarinic antagonists in asthma: An EAACI Position Paper","volume":"80","author":"Agache","year":"2025","journal-title":"Allergy"},{"key":"2025102211324753000_CS-2025-5452C96","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2025102211324753000_CS-2025-5452C97","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"2025102211324753000_CS-2025-5452C98","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"key":"2025102211324753000_CS-2025-5452C99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105609","article-title":"The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial","volume":"9","author":"Simpson","year":"2014","journal-title":"PLoS ONE"},{"key":"2025102211324753000_CS-2025-5452C100","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00031-2018","article-title":"Azithromycin treatment modifies airway and blood gene expression networks in neutrophilic COPD","volume":"4","author":"Baines","year":"2018","journal-title":"ERJ Open Res."},{"key":"2025102211324753000_CS-2025-5452C101","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1164\/rccm.201809-1739OC","article-title":"Long-term azithromycin reduces Haemophilus influenzae and increases antibiotic resistance in severe asthma","volume":"200","author":"Taylor","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C102","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/all.14768","article-title":"Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment","volume":"76","author":"Niessen","year":"2021","journal-title":"Allergy"},{"key":"2025102211324753000_CS-2025-5452C103","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/thoraxjnl-2020-216331","article-title":"Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy","volume":"76","author":"Shukla","year":"2021","journal-title":"Thorax"},{"key":"2025102211324753000_CS-2025-5452C104","first-page":"1821","article-title":"Inhaled phosphodiesterase inhibitors for the treatment of chronic obstructive pulmonary disease","volume":"81","author":"Singh","year":"2021","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025102211324753000_CS-2025-5452C105","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase iii trials (the ENHANCE Trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C106","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-2600(13)70187-5","article-title":"Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials","volume":"1","author":"Franciosi","year":"2013","journal-title":"Lancet Respir. Med"},{"key":"2025102211324753000_CS-2025-5452C107","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-019-1142-7","article-title":"Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD","volume":"20","author":"Singh","year":"2019","journal-title":"Respir. Res."},{"key":"2025102211324753000_CS-2025-5452C108","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1164\/rccm.202303-0455CI","article-title":"Targeting Type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook","volume":"208","author":"Rabe","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"Lancet Respir. Med"},{"key":"2025102211324753000_CS-2025-5452C110","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2025102211324753000_CS-2025-5452C111","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01296-2021","article-title":"The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)","volume":"59","author":"Sverrild","year":"2022","journal-title":"Eur. Respir. J."},{"key":"2025102211324753000_CS-2025-5452C112","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir. Med"},{"key":"2025102211324753000_CS-2025-5452C113","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00347-2024","article-title":"Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD","volume":"64","author":"Abdo","year":"2024","journal-title":"Eur. Respir. J."},{"key":"2025102211324753000_CS-2025-5452C114","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.mucimm.2024.12.001","article-title":"IL-33 is associated with alveolar dysfunction in patients with viral lower respiratory tract disease","volume":"18","author":"Scott","year":"2025","journal-title":"Mucosal Immunol"},{"key":"2025102211324753000_CS-2025-5452C115","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.mucimm.2023.07.002","article-title":"IL-33-induced neutrophilic inflammation and NETosis underlie rhinovirus-triggered exacerbations of asthma","volume":"16","author":"Curren","year":"2023","journal-title":"Mucosal Immunol"},{"key":"2025102211324753000_CS-2025-5452C116","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir. Med"},{"key":"2025102211324753000_CS-2025-5452C117","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-36642-y","article-title":"Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction","volume":"13","author":"England","year":"2023","journal-title":"Sci. Rep."},{"key":"2025102211324753000_CS-2025-5452C118","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir. Med"},{"key":"2025102211324753000_CS-2025-5452C119","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/thoraxjnl-2012-202432","article-title":"TNF\u03b1 antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial","volume":"68","author":"Aaron","year":"2013","journal-title":"Thorax"},{"key":"2025102211324753000_CS-2025-5452C120","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C121","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1183\/13993003.00148-2015","article-title":"A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis","volume":"46","author":"De Soyza","year":"2015","journal-title":"Eur. Respir. J."},{"key":"2025102211324753000_CS-2025-5452C122","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pupt.2015.02.001","article-title":"The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD","volume":"31","author":"Kirsten","year":"2015","journal-title":"Pulm. Pharmacol. Ther"},{"key":"2025102211324753000_CS-2025-5452C123","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/rccm.201405-0992OC","article-title":"CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease","volume":"191","author":"Rennard","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2025102211324753000_CS-2025-5452C124","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/15412555.2017.1335697","article-title":"A Randomized, placebo-controlled phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease","volume":"14","author":"Eich","year":"2017","journal-title":"COPD"},{"key":"2025102211324753000_CS-2025-5452C125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/15412555.2011.641803","article-title":"A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium","volume":"9","author":"Vogelmeier","year":"2012","journal-title":"COPD"},{"key":"2025102211324753000_CS-2025-5452C126","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.rmed.2012.12.009","article-title":"Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis","volume":"107","author":"Stockley","year":"2013","journal-title":"Respir. Med"},{"key":"2025102211324753000_CS-2025-5452C127","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jcf.2019.08.020","article-title":"Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis","volume":"19","author":"Barth","year":"2020","journal-title":"J. Cyst. Fibros"},{"key":"2025102211324753000_CS-2025-5452C128","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 Trial of the DPP-1 Inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2025102211324753000_CS-2025-5452C129","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-023-02444-z","article-title":"Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial","volume":"24","author":"Cipolla","year":"2023","journal-title":"Respir. Res."},{"key":"2025102211324753000_CS-2025-5452C130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cardfail.2023.04.003","article-title":"Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results","volume":"30","author":"Lam","year":"2024","journal-title":"J. Card. Fail."},{"key":"2025102211324753000_CS-2025-5452C131","doi-asserted-by":"crossref","first-page":"00347","DOI":"10.1183\/23120541.00347-2024","article-title":"Targeted DNase treatment of obstructive lung disease: a pilot randomised controlled trial","volume":"11","author":"Negewo","year":"2025","journal-title":"ERJ Open Res."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/139\/20\/1199\/979107\/cs-2025-5452.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/139\/20\/1199\/979107\/cs-2025-5452.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:33:09Z","timestamp":1761147189000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/139\/20\/1199\/236652\/COPD-the-role-of-neutrophils-in-inflammation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":131,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,22]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20255452","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10]]}}}